Palanosetrone Hydrocloride Injection

Indications

• Acid-base balance disorders
• pH adjustment in various medical solutions
• Chemical burns in controlled settings

Dosage

Children: Refer to specific clinical guidelines for appropriate dosing as it can vary based on the condition and clinical scenario.

Adults: Refer to specific clinical guidelines for appropriate dosing as it can vary based on the condition and clinical scenario.

Mechanism of action

The biological activity of hydrogen chloride is associated with its high solubility in water, where it dissociates almost completely. The hydrogen ion interacts with water molecules to form the hydronium ion, which acts as a proton donor with catalytic properties, allowing it to react with organic molecules. This interaction can lead to cellular injury and necrosis.

Pharmacodynamics

Hydrochloride exerts its effects primarily through the formation of hydronium ions, which lower the pH of the surrounding environment and can disrupt cellular processes. The acidic nature of this compound facilitates various chemical reactions that may affect cellular integrity and function.

Pharmacokinetics

As an acid, hydrochloride does not undergo traditional pharmacokinetic processes such as absorption, distribution, metabolism, and excretion in the same way as conventional drugs. Its effects are immediate upon exposure, as it dissociates in solution to exert its acidic properties.

Pregnancy

Hydrochloric acid is classified as category C, meaning risk cannot be ruled out. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether hydrochloric acid is excreted in human milk. Caution should be exercised when administered to breastfeeding women.

Storage

Store in a cool, dry place, away from light and tightly sealed to prevent moisture absorption.

Indications

• Chemotherapy-induced nausea and vomiting
• Postoperative nausea and vomiting
• Radiotherapy-induced nausea and vomiting

Dosage

Children: Refer to the BNF for Children for specific dosing based on age and indication.

Adults: Refer to clinical guidelines or prescribing information for specific dosing based on the indication.

Mechanism of action

Palanosetrone works by selectively antagonizing the serotonin 5-HT3 receptors located in the central nervous system and the gastrointestinal tract. By binding to these receptors, palanosetrone inhibits the action of serotonin, which is released during chemotherapy and can cause nausea and vomiting. This blockade helps to prevent the emetic response and provides symptomatic relief.

Pharmacodynamics

The pharmacodynamics of palanosetrone include its ability to prevent acute and delayed nausea and vomiting. The drug demonstrates high affinity for the 5-HT3 receptor, leading to effective antagonism. Its prolonged action results in sustained therapeutic effects, which is beneficial for patients undergoing chemotherapy. It has been shown to reduce the frequency and severity of nausea and vomiting significantly, thus improving the quality of life for patients.

Pharmacokinetics

Palanosetrone has favorable pharmacokinetic properties. It is rapidly absorbed following intravenous administration, with a peak plasma concentration reached within minutes. The drug has a long elimination half-life, which allows for once-daily dosing in many cases. It is metabolized primarily in the liver, with the involvement of cytochrome P450 enzymes. Excretion occurs mainly via the urine, with a small percentage excreted unchanged.

Contra-indications

• Hypersensitivity to palonosetron or any of its components
• Concomitant use with apomorphine due to the risk of severe hypotension

Adverse effects

• Headache
• Dizziness
• Constipation
• Fatigue
• QT prolongation
• Serious allergic reactions

Interactions

• May enhance the effects of other serotonergic drugs, increasing the risk of serotonin syndrome
• Caution with drugs that prolong the QT interval
• No significant interactions with CYP450 enzymes reported

Precautions

• Use with caution in patients with a history of cardiac arrhythmias
• Monitor patients for signs of serotonin syndrome when used with other serotonergic agents
• Consider potential for prolonged QT interval in susceptible populations

Pregnancy

Use during pregnancy only if clearly needed. Animal studies have shown no teratogenic effects, but adequate and well-controlled studies in pregnant women are lacking.

Breast-feeding

It is not known whether palonosetron is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store at room temperature, away from light and moisture. Do not freeze.

Formulations

• Injection solution (e.g., 0.25 mg/5 mL)
• Oral tablets (e.g., 0.5 mg)

Mechanism of action

The biological activity of hydrogen chloride is associated with its high solubility in water i.e., 23 moles/L at 0 °C. ... The hydrogen chloride in water dissociates almost completely, with the hydrogen ion captured by the water molecules to form the hydronium ion. The hydronium ion becomes a donor of a proton that possesses catalytic properties and thus is capable of reacting with organic molecules. This may explain the ability of hydrogen chloride to induce cellular injury and necrosis.